在性结肠炎中益生菌的临床前证据:系统性审查和网络元分析
Wenqin Jin1,2, Huangping Ai1,2, Qingqing Huang1,2
1Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in pharmacology
|June 26, 2023
概括
这项研究比较了性结肠炎的益生菌,发现不同的菌株有效减少炎症并改善肠道健康. 在临床前模型中,Lactobacillus rhamnosus和Enterococcus faecium在临床前模型中显示出特别的好处.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
背景情况:
- 胃肠道微生物失衡与慢性炎症性疾病,如性结肠炎有关.
- 益生菌可能有益于肠道微生物群,但它们在性结肠炎中的机制尚不清楚.
研究的目的:
- 在使用网络元分析的性结肠炎的临床前模型中比较各种益生菌的机制.
主要方法:
- 在PubMed,Embase和Web of Science数据库中搜索到2022年11月16日.
- 使用SYRCLE风险偏差工具评估研究质量.
- 包括42项研究,涉及839种性结肠炎模型和24种益生菌类型.
主要成果:
- 拉科巴西勒斯 (Lactobacillus rhamnosus) 在减轻体重减轻和改善香农指数方面表现出色.
- 在减少结肠损伤方面,Enterococcus faecium最有效.
- 乳杆菌reuteri降低了疾病活性指数 (DAI);乳杆菌酸性改善了组织学评分 (HIS) 和ZO-1表达;乳杆菌冠状菌降低了血清TNF-α.
结论:
- 益生菌可以通过改善组织病理学,减少炎症和修复粘膜屏障来改善性结肠炎.
- 特定的益生菌菌株在临床前模型中表现出明显的疗效.
- 需要进一步的高质量,大规模的临床前研究来证实这些发现.
相关概念视频
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
159
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
159
Drugs for Treatment of Ulcerative Colitis in IBD
179
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
179
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
360
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
360
Inflammatory Bowel Disease IV: Pharmacological Management
155
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
155
Peptic Ulcer Disease II: Pathophysiology
564
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
564
Inflammatory Bowel Disease I: Ulcerative Colitis
226
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
226


